Diabetes, Obesity and Metabolism - Volume 10, Issue 4, April 2008 (full text via interlibrary loan)

Review Articles

The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment
M. Andrikoula I. F. W. McDowell
pages 271–278

A cardiologist view of vascular disease in diabetes
Christopher J. Lockhart, Paul K. Hamilton, Katherine A. McVeigh Gary E. McVeigh
pages 279–292

Original Articles

The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus
G. Garcia-Soria, G. Gonzalez-Galvez, G. M. Argoud, M. Gerstman, T. W. Littlejohn III, S. L. Schwartz, A.-M. O’Farrell, X. Li, J. M. Cherrington, C. Bennett H.-P. Guler
pages 293–300

Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats
P. J. Larsen, E. M. Wulff, C. F. Gotfredsen, C. L. Brand, J. Sturis, N. Vrang,L. B. Knudsen K. Lykkegaard
pages 301–311

Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
R. E. Buckingham A. Hanna
pages 312–328

Continuous subcutaneous insulin infusion leads to immediate, stable and long-term changes in metabolic control
I. Aberle, D. Zimprich, B. Bach-Kliegel, C. Fischer, M. Gorny, A. Kliegel, K. Langer M. Kliegel
pages 329–335

Daily administration of the GIP-R antagonist (Pro3)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to antiobesity-diabetes actions of (Pro3)GIP
P. L. McClean, V. A. Gault, N. Irwin, J. T. McCluskey P. R. Flatt
pages 336–342

PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice
Y. S. Youn, J. E. Jeon, S. Y. Chae, S. Lee K. C. Lee
pages 343–346

Research Letters

Resveratrol blocks high glucoseinduced mitochondrial reactive oxygen species production in bovine aortic endothelial cells: role of phase 2 enzyme induction?
C. Lu, I. F. Bambang, J. S. Armstrong, M. Whiteman
pages 347–349

No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis
Josie M. M. Evans, Simon A. Ogston, Frank Reimann, Fiona M. Gribble, Andrew D. Morris Ewan R. Pearson
pages 350–352